Aspire Biopharma Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.1M
- Price
- $8.63
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.48%
- Volume
- 12.5K
About
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Quick stats
Shares outstanding1.4M
Computed float—
Float / sharesUnknown
Cash runway (months)14
Key info
SectorConsumer Cyclical
IndustryAuto - Parts
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001847345
Websitehttps://aspirebiolabs.com
AI Summary
AI-generated1/42
standardbullishbuyback
Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
Aspire-Lakewood Holdings' board authorized a $10 million common stock repurchase program effective September 9, 2026, with no expiration date.
The authorization is grounded in newly acquired subsidiary Dura Control Systems Corp, which generated approximately $209.5 million of revenue and $22.3 million of Adjusted EBITDA in audited FY2025, followed by roughly $103.9 million of revenue and $10.5 million of Adjusted EBITDA in the unaudited six months ended June 30, 2026.
With only about 1.5 million shares outstanding, management pegs 2025 Adjusted EBITDA at roughly $15.00 per share and argues the market price does not reflect the business; repurchases may occur in open market or private transactions but can be suspended or terminated at any time without notice.
Red flags
- Repurchase program is non-binding with no expiration date and may be suspended or terminated at any time without prior notice
- Only ~1.5 million shares outstanding — the $10M authorization may exceed a plausible market cap, raising execution, float and liquidity questions
- DCSC H1 2026 figures are unaudited and Adjusted EBITDA is a non-GAAP measure defined by DCSC; no GAAP net income is disclosed
- SOURCE line reads 'Aspire Biopharma Holdings, Inc.' despite the Aspire-Lakewood Holdings name and the release points to aspirebiolabs.com — identity/rebrand confusion plus a pre-revenue biopharma program layered on an automotive components business